Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply the latest evidence on currently available therapeutic strategies to optimize second-line treatment selection in EGFR-mutant metastatic NSCLC following progression on frontline tyrosine kinase inhibitor–based therapy
• Evaluate emerging data on PD-1×VEGF bispecifics in EGFR-mutant metastatic NSCLC to determine the potential impact on treatment sequencing

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Summit Therapeutics, Inc.

Chair:

Christine M. Lovly, MD, PhD, FASCO

Professor, Department of Medical Oncology and Therapeutics Research
Division Chief, Thoracic Medical Oncology
City of Hope Comprehensive Cancer Center
City of Hope National Medical Center
Duarte, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AnHeart Therapeutics, AstraZeneca, Bayer, Black Diamond Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Cepheid, D2G Oncology, Daiichi Sankyo, Danaher, Exact Sciences, Foresight Diagnostics, Foundation Medicine, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, InduPro, Jazz Pharmaceuticals, Johnson & Johnson, Merck, Natera, Nuvalent, Nuvation Bio, Onviv, Pfizer, Regeneron Pharmaceuticals, Summit Therapeutics, Taiho Oncology, Takeda, Tempus

Faculty:

Lyudmila Bazhenova, MD

Professor of Medicine
Medical Oncologist
Lung Cancer Unit Leader
Moores Cancer Center
University of California San Diego
La Jolla, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., Johnson & Johnson, Merck & Co., Inc., Natera, Inc., Nuvalent, Inc., Pfizer Inc., Revolution Medicines, Inc., Summit Therapeutics plc, Taiho Oncology, Inc.

Hossein Borghaei, DO, MS

Professor, Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Astellas, AstraZeneca, Axiom, Bayer, BeiGene, BerGenBio, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Gilead, Grid Therapeutics, Guardant, IO Biotech, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Novocure, Oncocyte, Pfizer, PharmaMar, Puma, RAPT, Regeneron, Summit, SystImmune, Takeda; Grant/Research funding: Amgen, Bristol Myers Squibb, Lilly; DSMB, Honorarium and Travel: Inspirna (formerly Rgenix, Stock Options), Nucleai (stock options), Sonnet Bio (Stock Options); Honoraria: Amgen, Daiichi Sankyo, Janssen, Jazz, Pfizer, Regeneron; Travel: Amgen, Bristol Myers Squibb, EMD Serono, Genentech, Jazz, Lilly, Merck, Mirati, Regeneron; Data and Safety Monitoring Board: Incyte, Novartis, Servier, SpringWorks, Takeda, University of Pennsylvania CAR T Program

Xiuning Le, MD, PhD

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology
Deputy Section Chief
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abion, Akeso, Allist, ArriVent, AstraZeneca, Avistone, Bayer, BioNTech, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Dizal, EMD Serono (Merck KGaA), Hengrui, Innovent, Johnson & Johnson (Janssen), Lilly, Merck, Novartis, Pfizer, Regeneron, Summit, SystImmune, Taiho, Teligene; Grant/Research funding: ArriVent, Dizal, EMD Serono, Johnson & Johnson (Janssen), Lilly, Regeneron, Takeda, Teligene, Thermo Fisher

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on EGFR resistance mechanisms and studies of subsequent lines of treatment following progression on EGFR-targeting TKIs, go to https://www.gotoper.com/smtd26egfrnsclc-activity.

Release Date

March 10, 2026

Expiration Date

March 10, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.